logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

Gene Dx Announces Evolution of Executive Leadership Team

Sep 12, 2023over 2 years ago

Position

Chief Growth Officer

Company

GeneDx

Melanie Duquette
Stamford

Description

Melanie Duquette joining team as Chief Growth Officer to drive commercial excellence, Jennifer Brendel to take new role as Chief of Corporate Affairs amplifying the GeneDx brand and leadership platform STAMFORD, Conn., Sept. 11, 2023 -- GeneDx a leader in delivering improved health outcomes through genomic and clinical insights, today announced the expansion and evolution of its executive leadership team with the appointment of Melanie Duquette as Chief Growth Officer and Jennifer Brendel as Chief of Corporate Affairs. Both executives will report to Katherine Stueland, CEO and President, and will collaborate in continuing to strengthen GeneDx’s market leading position in genomic interpretation and health insights. In her previous position as Chief Commercial Officer for GeneDx, Jen Brendel set the foundation of the commercial footprint and strategy for the Company, which has contributed to the accelerated utilization of exome and genome testing and 40% revenue growth from 2021 to 2022 with continued growth of product mix to 22% in Q2

Company Information

Company

GeneDx

Location

Stamford, Connecticut, United States

About

GeneDx is focused on delivering personalized, actionable insights that improve health outcomes. We sit at the intersection of diagnostics and data science, pairing decades of genomic expertise with an unmatched ability to interpret clinical data at scale. Our exome and genome testing is among the best in the industry. We expect that it will be even more advanced in the future with the help of Centrellis®, our innovative health information platform. Powered by millions of medical records, Centrellis® integrates digital tools with artificial intelligence to ingest and synthesize clinical and genomic data. As a result of our robust test menu, including our exome and genome testing, and the comprehensive insights generated by Centrellis®, we are developing a more complete understanding of complex disease than ever before. This translates to faster diagnosis, more effective treatment plans, and enhanced drug discovery. Our offerings help a whole spectrum of healthcare partners -- clinicians, researchers, health systems, pharmaceutical companies, and payors -- improve patient experiences and advance population health.

Related People

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months